GX Pharma
GX Pharma is a Beijing-headquartered Chinese CRO founded in 2008 that provides full-service clinical research, regulatory registration, and central lab services — with a CGT specialty — to pharmaceutical companies and innovation biotech firms across China, the US, Japan, and France.
- Company typePrivate
- Founded2008
- HeadquartersBeijing, China
- Headcount251–500
- GTM typeB2B
- OfferingServices
What GX Pharma does
GX Pharma (国信医药科技（北京）有限公司, legally Guoxin Pharmaceutical Technology (Beijing) Co., Ltd.) is a privately held China-based contract research organization (CRO) founded in 2008 and headquartered in Beijing Daxing District. The company delivers end-to-end clinical research services to pharmaceutical companies and biotech firms, with a portfolio spanning Phase I-IV clinical trials, medical affairs, regulatory registration and filing, post-marketing studies, data management and statistical analysis, third-party auditing, pharmacovigilance, SMO services, vaccine clinical research, and medical device clinical studies. Its primary customer segments are domestic and international innovation drug developers — particularly those working in Cell and Gene Therapy (CGT) — and traditional pharma and generic-drug companies seeking consistency evaluation and quality compliance support.
The company's differentiated technical platform centers on CGT clinical research capabilities covering CAR-NK, CAR-T, TCR-T, TIL, stem cell, iPSC, AAV gene therapy, ADC drugs, and nucleic acid drugs, which the company positions as a rare domestic specialty. Supporting this specialization, GX Pharma acquired a CNAS-qualified medical testing laboratory that provides central lab specimen testing, biomarker services, and hospital therapeutic drug monitoring (TDM). The organization operates through 8 wholly-owned subsidiaries — including Guoxin Zhongyan (Tianjin) for Traditional Chinese Medicine clinical research and the controlling-stake Guangzhou Yida New Drug — alongside 23 domestic offices and 3 overseas offices established in the United States, Japan, and France in 2019. The core management team is drawn from multinational pharma majors (Novartis, WuXi, Parexel, PRA, INC Research), and the company holds National High-Tech Enterprise status, ISO9001 certification, and three consecutive years (2017-2019) on the Top-20 China Pharmaceutical R&D Outsourcing list.
GX Pharma generates revenue through professional-services fees from project-based clinical research engagements with pharmaceutical groups and Tier-1 innovation biotech firms, both domestically and internationally. The company uses a direct enterprise sales model targeting innovation drug developers and operates with 500+ completed clinical trials, 300+ deep pharma partnerships, and a clinical network spanning 1,200+ tertiary hospitals and 900+ clinical research institutions. Revenue mix has shifted materially toward innovation drugs — from 27.19% of revenue in 2020 to a projected 70% in 2022 — with stated company-wide compound annual growth exceeding 70%. Since 2020, GX Pharma has raised approximately $43M USD across three funding rounds (Sep-2020, Oct-2021, Dec-2022) led by Yinyin Medical Fund, JHF Investment, and Puhua Capital, and has initiated preparations for a Shenzhen ChiNext IPO targeting a 2024-2026 reporting period.
GX Pharma firmographics
Firmographics- Name
- GX Pharma
- Legal name
- 国信医药科技（北京）有限公司
- Website
- https://gxcro.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- GX Pharma is a Beijing-headquartered Chinese CRO founded in 2008 that provides full-service clinical research, regulatory registration, and central lab services — with a CGT specialty — to pharmaceutical companies and innovation biotech firms across China, the US, Japan, and France.
- Ownership category
- akta.pro rank
GX Pharma industry classification
Industry- Product category
- Pharmaceutical Contract Research Organization (CRO) Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
- akta.pro secondary industries
- Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)
Keywords
Where GX Pharma is headquartered
LocationHeadquarters
- HQ city
- Beijing
- HQ country
- China
- HQ region
- Asia
Offices6 records
Markets served
GX Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- CRO临床研究服务: GX Pharma generates revenue primarily through providing clinical research organization (CRO) services including clinical studies, registration applications, medical affairs, post-marketing studies, data management, statistical analysis, third-party auditing, pharmacovigilance, SMO services, and vaccine clinical research. Revenue mix is shifting toward innovative drugs — innovation drug revenue was 27.19% in 2020 and projected to reach 70% by 2022.
- 中心实验室检测服务: Revenue from acquired medical testing laboratory (with CNAS qualifications) providing central laboratory specimen testing, biomarker laboratory services, and hospital TDM business
- 细胞基因治疗(CGT)临床研究服务: Specialized CGT clinical research services including CAR-NK, CAR-T, TCR-T, TIL, stem cell, iPSC, AAV gene therapy, ADC, and nucleic acid drugs — a fast-growing revenue stream with rapid order growth
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
GX Pharma product offering
Product offeringCore offering
GX Pharma is a Beijing-based Contract Research Organization (CRO) founded in 2008 that provides full-domain clinical research services to pharmaceutical companies and innovative-drug biotechs, including Phase I-IV clinical trials, medical affairs, regulatory registration and IND/NDA filing, data management and biostatistics, third-party audits, pharmacovigilance, SMO services, post-marketing studies, vaccine clinical research, and medical device studies. The company differentiates through a Cell and Gene Therapy (CGT) clinical innovation platform spanning CAR-NK, CAR-T, TCR-T, TIL, stem cell, iPSC, AAV gene therapy, ADC, and nucleic acid drugs, complemented by a CNAS-qualified central laboratory for specimen testing and biomarker analysis.\n\nChinese legal name: 国信医药科技（北京）有限公司
Product overview
GX Pharma（国信医药科技（北京）有限公司）是一家专注提供临床研究服务的CRO公司，采用平台+模块服务架构。公司成立于2008年，为国家级高新技术企业，主要提供临床研究服务、注册申报、数据管理、医学事务、药物警戒、SMO服务、医疗器械、疫苗临床研究等全流程服务。核心产品包括临床研究服务、基因细胞治疗实验平台、注册申报服务、中药临床研究服务（通过子公司国信中研）。公司在细胞与基因治疗（CGT）领域建立了一站式创新服务转化平台，涵盖CAR-NK、CAR-T、TCR-T、RAK、TIL、干细胞、IPSC、AAV基因治疗等多种CGT药物的临床研究服务。
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Research Services (Phase I-IV clinical studies for drugs, biologics, and vaccines)
- Medical Affairs Services
- Regulatory Registration and Filing Services
- Post-Marketing Research Services
- Data Management and Statistical Analysis Services
- Third-Party Audit Services
- Pharmacovigilance Services
- SMO (Site Management Organization) Services
- Medical Device Clinical Research Services
- Intellectual Property Services
- Vaccine Clinical Research Services
- Gene and Cell Therapy Experimental Innovation Platform
- Cell and Gene Therapy (CGT) CRO Services
- Traditional Chinese Medicine (TCM) Clinical Research Services
Quantifiable outcome
- 连续3年（2017-2019）荣获全国医药研发服务外包前20强
- +2 more outcomes
Companies that use GX Pharma
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
GX Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
GX Pharma partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and major.
- 国际医药创新公园（BioPark）minorGX Pharma受邀出席BioPark生态开放日活动，共探临床试验协同新路径。
- 广州医大新药创制有限公司（广医新药）majorGX Pharma控股收购广医新药，成为公司控股股东。GX Pharma法人、董事长陈永清博士兼任广医新药的法人、董事长。打造细胞治疗创新服务转化平台。
- 北京大学majorGX Pharma向北京大学捐资500万元人民币，用于支持北大全球健康发展研究院在卫生经济学领域的人才培养、政策研讨以及真实世界的研究工作。北京大学副校长王博、北大全球健康发展研究院院长刘国恩出席捐赠仪式。
Scale indicators12 records
Recent moves6 records
Expansion highlights7 records
GX Pharma competitors and assessment
Company assessmentDirect peers
- Hangzhou Tigermed (泰格医药): Tigermed is China's largest clinical CRO offering Phase I-IV clinical trial services, biostatistics, regulatory affairs, and site management across pharma and biotech — directly comparable to GX Pharma's core clinical CRO offering, though larger in scale and broader in therapeutic focus.
- WuXi AppTec (药明康德): WuXi AppTec is China's largest CRO/CDMO with an integrated clinical CRO (WuXi Clinical) and global footprint, providing end-to-end drug development services from discovery through clinical trials — directly comparable as a Chinese full-service clinical CRO competitor with much greater scale.
- Asymchem Laboratories (凯莱英): Asymchem is a leading Chinese CDMO/CRO with growing clinical research services for innovative drugs, serving domestic and international pharma/biotech — comparable in serving the same innovative-drug customer base as GX Pharma, though with a heavier CDMO/CMC orientation.
- Pharmaron (康龙化成): Pharmaron is a fully-integrated Chinese CRO/CDMO offering preclinical, CMC, and clinical research services to global pharma and biotech — directly comparable as a Chinese full-service CRO serving innovative drug developers, similar to GX Pharma's customer segments.
- Frontage Holdings (方达医药): Frontage is a US-headquartered but China-rooted CRO providing bioanalytical, CMC, and clinical trial services to innovative drug developers — comparable as a Chinese-origin clinical CRO serving pharma/biotech sponsors with similar service offerings.
- Medicilon (美迪西): Medicilon is a Shanghai-based preclinical and clinical CRO providing drug discovery, preclinical research, and clinical trial services to innovative drug companies — comparable as a Chinese CRO serving a similar biotech/pharma customer base with overlapping service offerings.
Broad incumbents
- IQVIA: IQVIA is the world's largest CRO with extensive clinical research, real-world evidence, and technology offerings, and is expanding operations in China — broadly comparable as a major incumbent clinical CRO that competes for the same multinational pharma and biotech sponsors.
- ICON plc: ICON (post-PRA Health Sciences acquisition) is one of the largest global CROs offering full-service clinical research, bioanalytical, and consulting services — comparable as a global incumbent CRO that competes with GX Pharma for innovative drug clinical trial contracts from multinational sponsors.
- Charles River Laboratories: Charles River is a global CRO with research models, preclinical, and clinical services for pharma/biotech, including CGT research support — comparable as a broad incumbent offering overlapping clinical CRO capabilities, particularly for cell and gene therapy sponsors.
- Fortrea (Labcorp Drug Development spinoff): Fortrea is the clinical CRO spun off from Labcorp, providing Phase I-IV clinical development services globally — comparable as a broad incumbent global CRO competing for the same multinational pharma/biotech clinical trial contracts.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
GX Pharma compliance and trust
Trust signalCompliance5 records
GX Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
GX Pharma leadership team
Management profileNumber of profiles
Profiles8 records
GX Pharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
GX Pharma funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GX Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GX Pharma
What does GX Pharma do?
GX Pharma is a Beijing-based Contract Research Organization (CRO) founded in 2008 that provides full-domain clinical research services to pharmaceutical companies and innovative-drug biotechs, including Phase I-IV clinical trials, medical affairs, regulatory registration and IND/NDA filing, data management and biostatistics, third-party audits, pharmacovigilance, SMO services, post-marketing studies, vaccine clinical research, and medical device studies. The company differentiates through a Cell and Gene Therapy (CGT) clinical innovation platform spanning CAR-NK, CAR-T, TCR-T, TIL, stem cell, iPSC, AAV gene therapy, ADC, and nucleic acid drugs, complemented by a CNAS-qualified central laboratory for specimen testing and biomarker analysis.\n\nChinese legal name: 国信医药科技（北京）有限公司
Is GX Pharma a public or private company?
GX Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was GX Pharma founded?
GX Pharma was founded in 2008. It employs 251 to 500 people.
Where is GX Pharma based?
GX Pharma is headquartered in Beijing, China, in the Asia region.
How does GX Pharma make money?
Three revenue lines are on record. CRO临床研究服务 is the primary driver. The others are 中心实验室检测服务 and 细胞基因治疗(CGT)临床研究服务.
Who are GX Pharma's main competitors?
Direct peers on record are Hangzhou Tigermed (泰格医药), WuXi AppTec (药明康德), Asymchem Laboratories (凯莱英), Pharmaron (康龙化成), Frontage Holdings (方达医药) and Medicilon (美迪西). Broad incumbents are IQVIA, ICON plc, Charles River Laboratories and Fortrea (Labcorp Drug Development spinoff).
Does GX Pharma have an API?
No public API is recorded for GX Pharma.
What industry is GX Pharma in?
GX Pharma's product category is Pharmaceutical Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA). Its NAICS code is 5417 and its SIC code is 8071.